Laurus Labs (LAURUSLABS) delivered a weak Q1FY25 due to lower revenue recorded in CDMO, FDFs and Bio and outperformance in generic APIs vs. our estimates.The API outperformed due to strong growth in oncology and other APIs. Gross margins improved, however, due to improved products mix, process improvements in large value APIs and reduced raw material costs.